

### NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE


# Single Technology Appraisal

Pegcetacoplan for treating primary complement 3 glomerulopathy and primary immune-complex membranoproliferative glomerulonephritis in people 12 years and over ID6489

## **Final Stakeholder List**

Provisional Consultees Provisional Commentators (no right to	
Provisional Consultees	Provisional Commentators (no right to submit or appeal)
	outsille or appeal)
Company	General
Swedish Orphan Biovitrum	All Wales Therapeutics and Toxicology
(pegcetacoplan)	Centre
	Allied Health Professionals Federation
Patient/carer groups	Association of Renal Industries
Kidney Care UK	Board of Community Health Councils in
Kidney Research UK	Wales
MPGN/DDD Support Group	British National Formulary
National Kidney Federation	Care Quality Commission
Polycystic Kidney Disease Charity	Department of Health - Northern Ireland
South Asian Health Foundation	Healthcare Improvement Scotland
Specialised Healthcare Alliance	<ul> <li>Medicines and Healthcare products Regulatory Agency</li> </ul>
Healthcare professional groups	National Association of Primary Care
<ul> <li>Association of Renal Industries</li> </ul>	National Pharmacy Association
Association of Renal Technologists	NHS Confederation
British Association of Paediatric	NHS Wales Joint Commissioning
Nephrology	Committee
British Association of Urological	Scottish Medicines Consortium
Nurses	Welsh Government
British Association of Urological	
Surgeons	Comparator companies
British Geriatrics Society	Alexion Pharma (eculizumab)
British Society for Immunology	Amgen (eculizumab)
Neonatal and Paediatric Pharmacists     Croup	Novartis (iptacopan)
Group	Roche (mycophenolate mofetil)
Royal College of General Practitioners     Poyal College of Nursing	Rosemont Pharmaceuticals
Royal College of Nursing     Poyal College of Pathologists	(mycophenolate mofetil)
Royal College of Physicians     Poyal College of Physicians	Samsung Bioepis (eculizumab)  Taya Pharma (myaanhanalata mafatil)
<ul><li>Royal College of Physicians</li><li>Royal Pharmaceutical Society</li></ul>	Teva Pharma (mycophenolate mofetil)  Tillamed Laboratoriae (mycophenolate
<ul> <li>Royal Pharmaceutical Society</li> <li>Royal Society of Medicine</li> </ul>	Tillomed Laboratories (mycophenolate     mofotil)
	mofetil)
Society for DGH Nephrologists     LIK Clinical Pharmacy Association	
UK Clinical Pharmacy Association	

Final stakeholder list for the evaluation of pegcetacoplan for treating primary complement 3 glomerulopathy and primary immune-complex membranoproliferative glomerulonephritis in people 12 years and over ID6489



Provisional Consultees	Provisional Commentators (no right to submit or appeal)
UK Kidney Association	Relevant research groups
<ul> <li>UK Renal Pharmacy Group</li> </ul>	Cochrane Kidney and Transplant Group
	Genomics England
<u>Others</u>	MRC Clinical Trials Unit
National Renal Complement	National Institute for Health Research
Therapeutics Centre	Society for Research in Rehabilitation
Department of Health and Social Care	Wellcome Trust
NHS England	
	Associated Public Health groups
	Public Health Wales
	UK Health Security Agency

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do not. Please let us know if we have missed any important organisations from the stakeholder list, and which organisations we should include that have a particular focus on relevant equality issues.

#### Definitions:

Consultee or commentator stakeholders are provisional until a signed Confidentiality Agreement & Undertaking form is submitted to NICE at the evaluation stage. Participating stakeholders will be listed on the project information page for the evaluation.

#### Consultees

Organisations that accept an invitation to participate in the evaluation; the company that markets the technology; national professional organisations; national patient organisations; the Department of Health and Social Care and relevant NHS organisations in England.

The company that markets the technology is invited to make an evidence submission, respond to consultations, nominate clinical experts and has the right to appeal against the Final Draft Guidance (FDG).


All non-company consultees are invited to submit a statement relevant to the group they are representing, respond to consultations, nominate clinical or patient experts and have the right to appeal against the Final Draft Guidance (FDG).

### **Commentators**

Organisations that engage in the evaluation process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations

Final stakeholder list for the evaluation of pegcetacoplan for treating primary complement 3 glomerulopathy and primary immune-complex membranoproliferative glomerulonephritis in people 12 years and over ID6489

Issue date: July 2025



and they receive the FDG for information only, without right of appeal. These organisations are: companies that market comparator technologies; Healthcare Improvement Scotland; related research groups where appropriate (for example, the Medical Research Council [MRC]); other groups (for example, the NHS Confederation and the British National Formulary).

All non-company commentators are invited to nominate clinical or patient experts.